

ICMR, Indian Immunologicals move monkey fever vaccine to Phase I trials

The two-dose adjuvanted inactivated vaccine was developed at the request of the Karnataka government, where the disease remains a regional concern.



New Delhi: The Indian Council of Medical Research in collaboration with Hyderabad-based Indian Immunologicals, has advanced an indigenous vaccine against Kyasanur Forest Disease (KFD) into

Phase 1 trials.

KFD also known as monkey fever is a vector-borne disease transmitted through ticks from monkeys to humans.

In India KFD is a regional infectious disease in the Western Ghats region, particularly, Karnataka, Tamil Nadu, Kerala, Goa, and Maharashtra.

The investigational candidate is a two dose adjuvanted inactivated vaccine and has been developed at the request from the Karnataka government.

Previously, the vaccine has completed toxicity studies and GLP-grade material has been manufactured.

According to ICMR, “If the Phase I trial is successful, further clinical trials will be initiated and if the vaccine is found to be safe and immunogenic, approval of CDSCO will be sought.”

A Phase I trial is the first step in testing a new drug or vaccine in humans, aimed at assessing safety, side effects, and appropriate dosage in a small group of healthy volunteers.

News Source:

<https://pharma.economictimes.indiatimes.com/news/pharma-industry/icmr-indian-immunologicals-move-monkey-fever-vaccine-to-phase-i-trials/128091326>